365 related articles for article (PubMed ID: 26238463)
1. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
3. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.
Mühlau M; Buck D; Förschler A; Boucard CC; Arsic M; Schmidt P; Gaser C; Berthele A; Hoshi M; Jochim A; Kronsbein H; Zimmer C; Hemmer B; Ilg R
Mult Scler; 2013 Oct; 19(11):1485-92. PubMed ID: 23462349
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.
De Stefano N; Giorgio A; Gentile G; Stromillo ML; Cortese R; Gasperini C; Visconti A; Sormani MP; Battaglini M
Ann Clin Transl Neurol; 2021 Mar; 8(3):623-630. PubMed ID: 33534940
[TBL] [Abstract][Full Text] [Related]
5. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
6. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
7. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
8. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Tur C; Tintoré M; Horga A; Auger C; Río J; Nos C; Edo MC; Arévalo MJ; Castilló J; Rovira A; Montalban X
Mult Scler; 2013 Aug; 19(9):1175-81. PubMed ID: 23319072
[TBL] [Abstract][Full Text] [Related]
9. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.
Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
Neurology; 2005 Mar; 64(6):1001-7. PubMed ID: 15781816
[TBL] [Abstract][Full Text] [Related]
10. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
11. Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B
Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800
[TBL] [Abstract][Full Text] [Related]
12. Gray matter atrophy is related to long-term disability in multiple sclerosis.
Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH
Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297
[TBL] [Abstract][Full Text] [Related]
13. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
[TBL] [Abstract][Full Text] [Related]
14. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
15. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.
Cortese R; Battaglini M; Sormani MP; Luchetti L; Gentile G; Inderyas M; Alexandri N; De Stefano N
Eur J Neurol; 2023 Jan; 30(1):179-186. PubMed ID: 36168741
[TBL] [Abstract][Full Text] [Related]
16. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
[TBL] [Abstract][Full Text] [Related]
19. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
[TBL] [Abstract][Full Text] [Related]
20. The role of global and regional gray matter volume decrease in multiple sclerosis.
Grothe M; Lotze M; Langner S; Dressel A
J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
